International Pharmacy Purchasing: Canadian Pharmacies, the Legal Landscape, and the Savings

Series 10, Article 05

The price differential between American and Canadian pharmacies for brand-name medications is not a marginal variance. It is a structural arbitrage opportunity that most level funded plans ignore because the legal framework appears prohibitive and the operational mechanisms appear complex. Both perceptions are partially correct and substantially misleading. For a small group plan with members on high-cost maintenance medications, international pharmacy purchasing can reduce pharmacy spend by 30% to 60% on specific drug categories. The legal landscape is more permissive than the statutory text suggests. The operational infrastructure exists and is accessible to any TPA willing to build the relationship.

This article examines the price differential, the legal framework that governs cross-border pharmacy purchases, the operational mechanisms that make implementation possible, and the net savings after accounting for risk and complexity.

The Price Differential

#

American prescription drug prices operate in a market that has repeatedly resisted the price controls common in peer countries. The result is documented and significant. A 2024 RAND Corporation analysis using 2022 data found that US drug prices were 278% of prices in 33 OECD comparison countries combined. For brand-name originator drugs, the differential was even larger: US prices averaged 422% of comparison country prices at manufacturer gross prices, and remained more than three times higher even after adjusting for estimated rebates (Mulcahy et al., “International Prescription Drug Price Comparisons”).

The differential is not uniform across drug categories. US prices for unbranded generics are actually lower than international comparisons, approximately 67% of combined OECD prices. Generic drugs account for 90% of US prescription drug volume but only 8% of spending. The savings opportunity in international purchasing is concentrated in brand-name drugs, and particularly in the high-cost specialty drug categories most relevant to level funded plans.

The RAND analysis provides country-specific comparisons. Canadian drug prices were 44% of US prices across all drugs, and 31% of US prices for brand-name originators specifically. France was at 22% of US prices for brand-name drugs, Germany at 26%, Japan at 22%. The differential means that a brand-name medication costing $1,000 per month in the US might cost $310 to $440 in Canada and $220 to $280 in France or Japan.

For the drug categories most relevant to small group plans, the savings are concrete. Semaglutide (Ozempic) retails at $900 to $1,100 per month in the United States. Canadian pharmacy pricing through CIPA-certified pharmacies runs $380 to $425 per month, a savings of approximately 60%. The differential exists because Canada’s Patented Medicine Prices Review Board (PMPRB) controls drug pricing through regulatory mechanisms that have no US equivalent.

The timing of generic entry compounds the differential. Generic semaglutide patent expiry occurred in Canada in January 2026. US patent protection extends at least through 2033, creating a seven-year window during which Canadian patients have generic access that American patients do not. For a plan member paying $12,000 per year for branded semaglutide, Canadian generic alternatives at 70% to 80% below US brand pricing represent $8,000 to $10,000 in annual savings per member.

The Legal Framework

#

The legal structure governing prescription drug importation is straightforward in its prohibition and complex in its enforcement. The Federal Food, Drug, and Cosmetic Act (FDCA) Section 801(d) prohibits the importation of prescription drugs that have not been approved by the FDA. The statute makes no distinction between personal use quantities and commercial importation. The prohibition appears absolute.

Enforcement reality diverges substantially from statutory text. The FDA has maintained a Personal Importation Policy that exercises enforcement discretion for personal use importation under specific conditions. The policy permits FDA personnel to allow importation when the product is for personal use in quantities appropriate to that use (typically a 90-day supply), the patient affirms the product is for their own use, the product does not present an unreasonable risk, and no commercialization or promotion to US residents has occurred (“Personal Importation For Import Program”).

The practical result: seizure rates for personal-use orders from CIPA-certified Canadian pharmacies remain below 0.1%. The enforcement discretion applies to individuals ordering maintenance medications for their own use, not to commercial importation schemes or bulk purchasing.

State-level importation programs operate under a different statutory framework. Section 804 of the FDCA, as amended, authorizes the Secretary of Health and Human Services to permit states and Indian tribes to import certain prescription drugs from Canada if the importation poses no additional risk to public health and safety and results in significant cost savings. Florida became the first state to receive FDA authorization under this Section 804 Importation Program (SIP) in January 2024. The authorization has been extended through May 2026, though actual drug shipments have faced implementation delays related to FDA drug-by-drug approval requirements and Canadian export controls (HUB International).

The Canadian government has complicated state importation programs. Following FDA approval of Florida’s SIP, Health Canada issued guidance referencing provisions in Canada’s Food and Drugs Act that prohibit certain drugs intended for the Canadian market from being sold for consumption outside Canada if that sale could cause or worsen a domestic drug shortage. The concern is legitimate: US demand could drain Canadian supply for drugs already facing shortage conditions. Export controls have tightened, particularly around high-demand medications like GLP-1 agonists.

For self-funded plans, the legal analysis requires distinguishing between three scenarios. First, facilitating member access to licensed Canadian pharmacies for personal importation operates in the enforcement discretion zone that has applied for two decades. The plan does not import drugs; members import drugs for personal use. Second, bulk importation for plan distribution would require state SIP authorization or similar FDA-approved pathway and is not currently available to employer plans. Third, directing members to CIPA-certified pharmacies and providing educational materials about international pharmacy options creates minimal legal exposure because the plan is providing information, not importing drugs.

The Operational Mechanisms

#

The Canadian International Pharmacy Association (CIPA) provides the verification infrastructure that makes safe international pharmacy purchasing possible. CIPA was established in 2002 to create a unified standard for Canadian pharmacies serving international patients. Membership requires provincial pharmacy licensing, Health Canada compliance, and adherence to CIPA’s operational standards (“CIPA Certification”).

CIPA certification requirements include: requiring a valid prescription before dispensing medications; maintaining a patient health profile with medication history to prevent adverse drug interactions; having a licensed pharmacist on staff for patient consultation; and complying with Health Canada regulations governing pharmaceutical distribution. Only 51 pharmacy websites currently meet CIPA standards. The organization has maintained a 100% safety record across more than 10 million patients served since 2002 (“Buying Safe Online Prescription Drugs from Canada”).

The operational process for a self-funded plan integrating international pharmacy access follows a consistent pattern. The plan designates specific high-cost drug categories as eligible for international pharmacy benefit. Eligible categories typically include brand-name maintenance medications without US generic alternatives, high-cost specialty drugs, and drugs with significant Canada-US price differentials. Members on eligible medications receive enrollment information and are referred to CIPA-certified pharmacies.

Prescription transfer and fulfillment follows CIPA pharmacy procedures. Members provide a valid US prescription. The Canadian pharmacy verifies the prescription with the prescribing physician. Medication is dispensed from the Canadian pharmacy and shipped via mail order, typically in 90-day quantities. The process mirrors US mail-order pharmacy procedures with the addition of customs clearance.

For a TPA building international pharmacy capability, the infrastructure requirements include: a partnership or referral arrangement with one or more CIPA-certified pharmacies; member communication and enrollment processes; prescription verification procedures; a benefit design that specifies which drugs are eligible for international pharmacy fulfillment; and member support for questions about the process.

The implementation cost is modest. CIPA-certified pharmacies handle all dispensing, shipping, and customs processes. The TPA’s role is member navigation, benefit design, and enrollment support. The operational infrastructure is simpler than domestic pharmacy benefit management because the TPA is referring members to established pharmacy services rather than managing a proprietary network.

Savings Quantified and Risk Assessed

#

The savings calculation for a representative small group plan demonstrates the magnitude of the opportunity. Consider a 25-person plan with four members on high-cost brand-name maintenance medications. Member profiles: two members on branded GLP-1 agonists at $12,000 per year each (US pricing), one member on a specialty biologic at $40,000 per year, one member on a branded cardiovascular medication at $6,000 per year. Total annual pharmacy spend for these four members: $70,000 under US pricing.

Canadian pharmacy pricing reduces these costs by 40% to 60% for brand-name drugs. At a conservative 40% reduction, annual savings would be $28,000. At 60%, savings would be $42,000. Against an expected claims fund of $375,000, the pharmacy savings alone represent 7% to 11% of total expected claims.

The savings concentration is significant. Four members generate the savings, but the savings benefit the entire plan through reduced claims fund draw and potential surplus recovery. The members who switch to international pharmacy benefit directly through reduced out-of-pocket costs if the plan design shares savings with members.

The risk assessment requires disaggregating legal risk, operational risk, and member acceptance risk. Legal risk under the personal importation enforcement discretion framework has been minimal for two decades. The FDA has not pursued individual patients or their employers for personal-use importation from licensed Canadian pharmacies. This enforcement posture could change, but the practical risk under current policy is low.

Operational risk relates to medication quality and supply reliability. CIPA certification addresses quality risk through its verification and safety record. Supply reliability is a genuine concern: Canadian pharmacies face supply constraints on high-demand medications, particularly GLP-1 agonists. Members may need to maintain backup domestic pharmacy access for drugs subject to supply disruption.

Member acceptance risk is the most significant barrier. Some members will be uncomfortable purchasing medications from international pharmacies regardless of safety certification. The plan cannot mandate international pharmacy use; it can only incentivize it. Benefit designs that share savings with members through reduced copays or premium contributions for international pharmacy participation increase acceptance rates.

The net assessment: for plans with significant brand-name drug exposure, international pharmacy purchasing represents recoverable savings that justify the operational complexity. The legal framework is more permissive than statutory text suggests, the operational infrastructure exists through CIPA-certified pharmacies, and the member acceptance barrier can be addressed through thoughtful benefit design. A TPA that builds this capability creates value that most competitors have not captured.